The Pharma Data
JULY 8, 2021
“We are proud to advance an innovative, first-in-class monoclonal antibody that targets the top of the inflammatory cascade and represents a potentially transformative treatment option for a broad population of patients with severe asthma. Ann Allergy Asthma Immunol. World Allergy Organization (WAO). EMJ Allergy Immunol.
The Pharma Data
NOVEMBER 9, 2020
About Tezepelumab Tezepelumab is an investigational, potential first-in-class human monoclonal antibody that works on the primary source of inflammation: the airway epithelium, which is the first point of contact for viruses, allergens, pollutants, and other environmental insults. 10 World Allergy Organization (WAO). 11 Busse WW.
XTalks
DECEMBER 24, 2020
Most antibody drugs and vaccines have been developed to target parts of the spike protein. These include remdesivir, baricitinib, dexamethasone and three antibody drugs. Antibody drugs were also developed as targeted COVID-19 treatments. Drug Approvals. Vaccine Considerations.
Expert insights. Personalized for you.
52 
Let's personalize your content